Adaptive Biotechnologies Corporation (ADPT) Leapt 18% In Extended Trading. Here’s Why?
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, has seen its share price surging 18.16% in extended trading to $49.90.
Insider Alert: Adaptive Biotechnologies Corporation [ADPT]’s Dir, Dobmeier Eric, Makes A $573,369 Sell
On Jan. 04, Dobmeier Eric divested U.S. $573,369 in shares of Adaptive Biotechnologies Corporation. The Dir sold 10,000 shares at a price per share of $57.34. The transaction decreased this specific insider’s holdings to 0 shares worth around $0.0 at present. Another 6,771 shares were sold by Benzeno Sharon, for more than $388,583 in total […]
